Celgene adds $2 billion to stock repurchase plan
This article was originally published in Scrip
Executive Summary
Celgene says that its board has authorised the addition of $2 billion to its stock repurchase plan, through an open-ended programme. The biopharmaceutical company focused on cancer and inflammatory diseases is just one of several firms recently to use stock buyback to boost investors' confidence.